THE EFFECTS OF LOW-DOSE RITONAVIR ON THE RENAL CLEARANCE OF TENOFOVIR

小剂量利托那韦对替诺福韦肾清除率的影响

• 批准号: 7377825
• 负责人: MONICA CARTEN
• 金额: $ 7.22万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377825
• 关键词: EFFECTS; LOW; DOSE; RITONAVIR; RENAL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There have recently been reports of patients with human immunodeficiency virus (HIV) developing kidney toxicities while taking the drug Viread¿. Many of these patients were also taking low-dose (100 mg once or twice daily) ritonavir as part of their HIV treatment regimen. This study is designed to test if the toxicities observed in HIV patients taking Viread¿ might be caused by a drug interaction in the kidney between Viread¿ and ritonavir. The purpose of this study is to test whether there are differences in the amount of Viread¿ the kidneys excrete into the urine in patients who are taking a HIV regimen containing low-dose ritonavir (as Kaletra¿) compared to patients who are taking a HIV regimen that does not contain a protease inhibitor. This study will require 2 study visits: one screening visit (approximately 1 hour in length) and one 24-hour overnight visit. Study participants will use their own supply of HIV medications for the study. Blood and urine samples will be collected at both visits to look for the levels of Viread¿ in these fluids. We will compare the levels of Viread¿ in the urine and blood between the 2 groups of patients. We will also draw blood to look at DNA, or inherited genetic material. The DNA will be used to determine the body's inherited ability to absorb, metabolize, transport, eliminate, and respond to HIV medications.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。最近有报道称，人类免疫缺陷病毒 (HIV) 患者在服用 Viread 药物时出现肾毒性。其中许多患者还服用低剂量（100 毫克，每天一次或两次）利托那韦作为 HIV 治疗方案的一部分。本研究旨在测试服用 Viread 的 HIV 患者中观察到的毒性是否可能是由 Viread 和利托那韦之间的肾脏药物相互作用引起的。本研究的目的是测试服用含有低剂量利托那韦（如克力芝）的 HIV 治疗方案的患者与服用不含蛋白酶抑制剂的 HIV 治疗方案的患者相比，肾脏排泄到尿液中的 Viread 量是否存在差异。这项研究需要 2 次研究访视：一次筛选访视（时长约 1 小时）和一次 24 小时过夜访视。研究参与者将使用自己的艾滋病毒药物来进行研究。两次就诊时都会收集血液和尿液样本，以检测这些液体中 Viread 的水平。我们将比较两组患者尿液和血液中 Viread 的水平。我们还将抽血检查 DNA，即遗传物质。 DNA将用于确定人体吸收、代谢、运输、消除和响应HIV药物的遗传能力。